Breast Cancer in 2023 and Beyond

Peter Kaufman, MD
University of Vermont, Burlington, VT, USA

Hope Rugo, MD
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

William Sikov, MD
Women & Infants Hospital of Rhode Island, Providence, RI, USA

Heather McArthur, MD, MPH
University of Texas Southwestern Medical Center, Dallas, TX, USA

Peter Beitsch, MD
Dallas Breast Cancer, Dallas, TX, USA

Banu Arun, MD
University of Texas MD Anderson Cancer Center, Dallas, TX, USA

Kelly McCann, MD, PhD
UCLA Medicine, Los Angeles, CA, USA

The meeting report will be based on the following topics

• Current and Emerging Biomarkers and Testing Methodologies in Breast Cancer
• The Changing Landscape of HER2+ Early Breast Cancer
• Maximizing Potential Targeting of HER2 in HER2+ mBC
• Clinical Implications of HER2-Low Breast Cancer
• Standard and Emerging Strategies for High-Risk, Early-Stage, Triple-Negative Breast Cancer
• Current and Investigational Approaches in Metastatic Triple-Negative Breast Cancer
• Therapeutic Horizons in HR+ Early Breast Cancer
• Therapeutic Horizons in HR+ Advanced Breast Cancer
• Old and New Targets in Breast Cancer
• Future Directions in Breast Cancer Treatment